Operating Segments (Tables)

12 Months Ended

Dec. 31, 2013

Operating Segments [Abstract]

Summary of segmental information

	For the Year Ended December 31,
	2013			2012
Revenues
Vaccines/BioDefense	$	3,003,822		$	2,919,677
BioTherapeutics		220,330			224,943
Total	$	3,224,152		$	3,144,620
Loss from Operations
Vaccines/BioDefense	$	(1,666,130	)	$	(33,636	)
BioTherapeutics		(3,069,998	)		(2,203,721	)
Corporate		(2,420,414	)		(2,453,311	)
Total	$	(7,156,542	)	$	(4,690,668	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	37,981		$	38,589
BioTherapeutics		190,033			190,003
Corporate		2,057			2,038
Total	$	230,071		$	230,630
Interest Income
Corporate	$	1,960		$	6,202
Stock-Based Compensation
Vaccines/BioDefense	$	80,432		$	44,484
BioTherapeutics		250,431			84,020
Corporate		472,197			333,666
Total	$	803,060		$	462,170

	As of December 31,
	2013		2012
Identifiable Assets
Vaccines/BioDefense	$	1,870,414	$	628,494
BioTherapeutics		386,721		566,111
Corporate		6,008,320		3,510,499
Total	$	8,265,455	$	4,705,104